Largest biotech by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total assets, at SGD 116.8B, ahead of Gilead Sciences (SGD 76.1B) and Biogen (SGD 38B). Figures as of 18 Nov 2026, 15:38 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSGD 116.8B
- Median
- SGD 3.3B
- Combined market value
- SGD 1.09T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SGD 116.8B | SGD 313B | SGD 578.70 | 2.02% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SGD 76.1B | SGD 270.3B | SGD 217.92 | 0.76% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | SGD 38B | SGD 47.5B | SGD 321.55 | 0.59% down | 49% up | ||
| 4 | BioNTechBNTX · Health Care | SGD 31.5B | SGD 26.9B | SGD 108.44 | 0.93% down | 16% down | ||
| 5 | ModernaMRNA · Health Care | SGD 15.9B | SGD 105.9B | SGD 261.81 | 1.84% down | 755% up | ||
| 6 | argenxARGX · Health Care | SGD 11.2B | SGD 77.2B | SGD 1,228.01 | 0.49% up | 4% up | ||
| 7 | QiagenQGEN · Health Care | SGD 8.1B | SGD 13.2B | SGD 63.95 | 0.33% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SGD 6B | SGD 21.2B | SGD 209.07 | 2.30% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | SGD 3.9B | SGD 11.8B | SGD 74.44 | 2.83% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | SGD 3.8B | SGD 14.1B | SGD 220.44 | 5.39% up | 5% up | ||
| 11 | ExelixisEXEL · Health Care | SGD 3.7B | SGD 21.6B | SGD 88.72 | 0.42% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | SGD 3.3B | SGD 14.7B | SGD 93.79 | 0.13% up | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | SGD 3.3B | SGD 14.3B | SGD 125.14 | 1.10% up | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | SGD 3B | SGD 44.6B | SGD 206.05 | 1.80% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SGD 2.9B | SGD 5.1B | SGD 53.07 | 2.48% up | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | SGD 2.2B | SGD 13.4B | SGD 156.63 | 0.06% down | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | SGD 1.7B | SGD 11.7B | SGD 396.19 | 2.89% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | SGD 1.2B | SGD 9B | SGD 43.43 | 1.39% up | 43% up | ||
| 19 | CG OncologyCGON · Health Care | SGD 1B | SGD 9.2B | SGD 103.33 | 1.49% up | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | SGD 827.8M | SGD 10B | SGD 146.53 | 1.44% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | SGD 661.3M | SGD 5.9B | SGD 36.75 | 0.02% up | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | SGD 647.3M | SGD 9.1B | SGD 8.53 | 5.70% up | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | SGD 521.4M | SGD 7.5B | SGD 61.17 | 5.21% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | SGD 453.4M | SGD 8.2B | SGD 126.14 | 1.03% up | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2897 SGD).
Questions and answers
Which biotech rank first by total assets?
Amgen (SGD 116.8B), Gilead Sciences (SGD 76.1B) and Biogen (SGD 38B) are the top three of the 24 biotech ranked by total assets as of 18 Nov 2026, 15:38 UTC.
How many biotech are in this ranking?
24 are ranked by total assets.
What are these biotech worth together?
The 24 biotech ranked by total assets have a combined market value of SGD 1.09T as of 18 Nov 2026, 15:38 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.